drugset
drugset / Trial / NCT06223828

Azithromycin for Critical Asthma - Pediatrics

NCT06223828 ↗

Phase 2/3 Recruiting 100 enrolled Johns Hopkins All Children's Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The CR-AZI Study will assess the immunomodulatory effects of Azithromycin for pediatric Critical Asthma.

Timeline

Start
2024-04-02
Primary completion
2026-07-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Azithromycin Small molecule 10 mg/kg —

Indications

childhood onset asthma critical illness polyneuropathy